At present, the potential factors associated with the prognosis of nAMD after anti-VEGF therapy are primarily based on baseline clinical characteristics, such as age [9, 10], baseline visual acuity (VA) [11, 12], and the choroidal neovascularization (CNV) lesion area [13], as well as several optical coherence tomography (OCT) characteristics such as the status of the external limiting membrane (ELM) and ellipsoid zone (EZ) [14]. The gene discussed is VEGFA; the disease is choroidal neovascularization.